CFAP20

Across TCGA pan-cancer cohorts, CFAP20 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CFAP20 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CFAP20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP20 expression acts as an unfavorable survival marker.

PDAC, LSCC, and LUAD are the cancer types where CFAP20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.694	0.946	.002	21	view →
LSCC	OS	Tertile	All	0.903	1.000	.015	5	view →
LUAD	DFS	Median	All	0.899	0.932	.021	1	view →
HNSC	OS	Tertile	All	0.606	0.847	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CFAP20–PDAC (OS)

Open the PDAC breakdown →